
               
               
               7 DRUG INTERACTIONS
               
                  Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John’s wort) may significantly decrease exposure to exemestane. Dose modification is recommended for patients who are also receiving a strong CYP 3A4 inducer [see 
                     Dosage and Administration (2.2) and
                     Clinical Pharmacology (12.3)].
               
               
               
                  
                     
                        
                           
                              •Strong CYP 3A4 inducers: Concomitant us of strong CYP 3A4 inducers decreases Exemestane exposure. Increase the exemestane dose to 50 mg (2.2, 7).
                        
                     
                  
               
            
         